Delving into the Latest Updates on Logical Therapeutics, Inc. with Synapse

Overview

LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed. This trial will compare the rate of gastric ulcer by endoscopy over three months in patients with knee osteoarthritis, with patients receiving either LT-NS001 at a dose which provides comparable dose levels of Naproxen, or Naprosyn® 500mg (an approved treatment for OA).

Start Date01 Feb 2010

Sponsor / Collaborator

Logical Therapeutics, Inc.

[+1]

NL-OMON31529 / CompletedNot Applicable

A SINGLE-BLIND, RANDOMIZED, ESCALATING MULTIPLE DOSE STUDY (PART 1) AND A SEVEN TREATMENT CROSSOVER BIOAVAILABILITY STUDY (PART 2) OF LT-NS001 AND NAPROXEN ADMINISTERED IN HEALTHY SUBJECTS - LT-NS001 escalating multiple dose and bioavailability study

Start Date21 Nov 2008

Sponsor / Collaborator

Logical Therapeutics, Inc.

100 Clinical Results associated with Logical Therapeutics, Inc.

Login to view more data

0 Patents (Medical) associated with Logical Therapeutics, Inc.

Login to view more data

3

Literatures (Medical) associated with Logical Therapeutics, Inc.

01 Oct 2008·Kidney InternationalQ1 · MEDICINE

Animal models of sepsis and its complications

Q1 · MEDICINE

Review

Author: Fink, Mitchell P

Most currently used animal sepsis models fail to adequately replicate the clinical problem and, therefore, have only limited utility for investigating pathophysiological mechanisms or testing the efficacy of new therapeutic agents. Recent experimental findings support this view and suggest that models of acute infection in mice with pre-existing renal dysfunction may be useful in the development pathway for new therapeutic agents for sepsis.

01 May 2008·The American Journal of PathologyQ2 · MEDICINE

Neuropeptide Modulators of High Mobility Group Box 1 Secretion as Potential Therapeutic Agents for Severe Sepsis

Q2 · MEDICINE

Article

Author: Fink, Mitchell P

A review.The research of Chorny and Delgado (2008) entitled, "Neuropeptides rescue mice from lethal sepsis by downregulating the secretion of the late-acting inflammatory mediator high mobility group box 1" is reviewed with commentary and referencesThe authors reported that treatment with endogenous neuropeptides, either vasoactive intestinal peptide or urocortin, can improve survival in a clin. relevant animal model of lethal sepsis.They found that vasoactive intestinal peptide (VIP) and urocortin inhibit active secretion of high mobility group box 1 (HMGB1) by lipopolysaccharide (LPS)-stimulated murine macrophages.Lastly, they notably showed that endogenous release of VIP and/or urocortin might serve a counterregulatory role in vivo to modulate the proinflammatory effects of HMGB1 secretion.

01 Apr 2008·Current Opinion in AnaesthesiologyQ3 · MEDICINE

Ethyl pyruvate

Q3 · MEDICINE

Review

Author: Fink, Mitchell P

PURPOSE OF REVIEWEthyl pyruvate is a simple derivative of the endogenous metabolite, pyruvic acid. Ethyl pyruvate was shown to ameliorate some of the structural and functional changes associated with mesenteric ischemia and reperfusion in rats.RECENT FINDINGSTreatment with ethyl pyruvate has been shown to improve survival and ameliorate organ dysfunction in a wide variety of preclinical models of critical illnesses, such as severe sepsis, acute respiratory distress syndrome, burn injury, acute pancreatitis and stroke. Ethyl pyruvate has been shown to improve cardiac function after coronary ischemia and reperfusion. This ester was originally regarded as a way to administer pyruvate, while avoiding some of the problems associated with the instability of pyruvate in aqueous solutions. Increasingly, however, it is becoming apparent that certain pyruvate esters, including ethyl pyruvate, have pharmacological effects, such as suppression of inflammation, which are distinct from those exerted by pyruvate anion. Ethyl pyruvate has been tested in human volunteers and shown to be safe at clinically relevant doses.SUMMARYEthyl pyruvate is a simple molecule that has been shown to have salutary effects in numerous large and small animal models of critical illness. It remains to be determined whether this ester can be used successfully to treat human diseases.

100 Deals associated with Logical Therapeutics, Inc.

Login to view more data

100 Translational Medicine associated with Logical Therapeutics, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LT-ZP001	Diabetes Mellitus, Type 2 More	Discontinued
LT-ZMP001 ( TNFR1 )	Rheumatoid Arthritis More	Discontinued
LT-NS108 ( COX-2 )	Inflammation More	Pending
Naproxen Etemesil ( COX )	Stomach Ulcer More	Pending